CXCL8: Interleukin-8
Chemotactic factor that mediates inflammatory response by attracting neutrophils, basophils, and T-cells to clear pathogens and protect the host from infection.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on CXCL8, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
| ABX-IL8 | Phase 2 | Abgenix | Other | InhibitorInterleukin-8 inhibitor | 0 |
| Adakitug | Phase 2 | Bristol-Myers Squibb | Antibody | InhibitorInterleukin-8 inhibitor | 0 |
- Coronary artery disorder0.37
- Myocardial infarction0.36
- Ischemic stroke0.35
- Placenta praevia0.20
- Endocrine system disorder0.19
- Hepatocellular carcinoma0.14
- Melanoma0.14
- Chronic obstructive pulmonary disease0.14
- Pancreatic ductal adenocarcinoma0.14
- Contact dermatitis0.13
- Non-small cell lung carcinoma0.13
- Head and neck squamous cell carcinoma0.13
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2157, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P10145, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets